Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates,omega-3 fatty acid compounds, and PCSK9 inhibitors, are utilized to improve lipid levels with the goal of CV risk reduction. Statins dominate the dyslipidemia market owing to their good risk-benefit profile and evidence for reducing CV morbidity and mortality. However, the later-line treatment paradigm is evolving owing to the emergence of novel drug classes and more-positive outcomes data for the established agents. Using a longitudinal claims data analysis, we demonstrate how newly diagnosed and recently treated dyslipidemia patients are treated in the United States.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Amarin, Esperion Therapeutics, Amgen, Novartis, Regeneron, Merck, Pfizer, AstraZeneca, Kowa Pharmaceuticals, Medicure Pharmaceuticals
Key drugs: Nexletol, Nexlizet, Vascepa, Repatha, Praluent, Leqvio, statins, fibrates, cholesterol absorption inhibitors.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.